Vanessa Hinson to Humans
This is a "connection" page, showing publications Vanessa Hinson has written about Humans.
Connection Strength
0.210
-
Validation of a Behavioral Approach for Measuring Saccades in Parkinson's Disease. J Mot Behav. 2017 Nov-Dec; 49(6):657-667.
Score: 0.021
-
Assessing Visuospatial Skills in Parkinson's: Comparison of Neuropsychological Assessment Battery Visual Discrimination to the Judgment of Line Orientation. Arch Clin Neuropsychol. 2017 Feb; 32(1):123-127.
Score: 0.021
-
Robustness of reliable change indices to variability in Parkinson's disease with mild cognitive impairment. Appl Neuropsychol Adult. 2016 Nov-Dec; 23(6):399-402.
Score: 0.020
-
Immediate vs. delayed treatment of psychogenic movement disorders with short term psychodynamic psychotherapy: randomized clinical trial. Parkinsonism Relat Disord. 2014 Jan; 20(1):60-3.
Score: 0.017
-
Mattis Dementia Rating Scale cutoffs are inadequate for detecting dementia in Parkinson's disease. Appl Neuropsychol Adult. 2013; 20(1):61-5.
Score: 0.016
-
Reducing dosing frequency of carbidopa/levodopa: double-blind crossover study comparing twice-daily bilayer formulation of carbidopa/levodopa (IPX054) versus 4 daily doses of standard carbidopa/levodopa in stable Parkinson disease patients. Clin Neuropharmacol. 2009 Jul-Aug; 32(4):189-92.
Score: 0.013
-
Disrupted thalamic prefrontal pathways in patients with idiopathic dystonia. Parkinsonism Relat Disord. 2009 Jan; 15(1):64-7.
Score: 0.012
-
Structural white matter abnormalities in patients with idiopathic dystonia. Mov Disord. 2007 Jun 15; 22(8):1110-6.
Score: 0.011
-
Psychogenic movement disorders. Lancet Neurol. 2006 Aug; 5(8):695-700.
Score: 0.010
-
Rating scale for psychogenic movement disorders: scale development and clinimetric testing. Mov Disord. 2005 Dec; 20(12):1592-7.
Score: 0.010
-
Therapies for movement disorders. Arch Neurol. 2002 May; 59(5):699-702.
Score: 0.008
-
Effect of Urate-Elevating Inosine on Early Parkinson Disease Progression: The SURE-PD3 Randomized Clinical Trial. JAMA. 2021 09 14; 326(10):926-939.
Score: 0.007
-
Update on viral encephalitis. Curr Opin Neurol. 2001 Jun; 14(3):369-74.
Score: 0.007
-
Cognitive function in 1736 participants in NINDS Exploratory Trials in PD Long-term Study-1. Parkinsonism Relat Disord. 2016 12; 33:127-133.
Score: 0.005
-
A randomized clinical trial of high-dosage coenzyme Q10 in early Parkinson disease: no evidence of benefit. JAMA Neurol. 2014 May; 71(5):543-52.
Score: 0.004
-
Multisite, double-blind, randomized, controlled study of pregabalin for essential tremor. Mov Disord. 2013 Feb; 28(2):249-50.
Score: 0.004
-
Reduced parietal activation in cervical dystonia after parietal TMS interleaved with fMRI. Clin Neurol Neurosurg. 2012 Sep; 114(7):914-21.
Score: 0.004
-
Flexible analytical methods for adding a treatment arm mid-study to an ongoing clinical trial. J Biopharm Stat. 2012; 22(4):758-72.
Score: 0.004
-
Dysautonomia rating scales in Parkinson's disease: sialorrhea, dysphagia, and constipation--critique and recommendations by movement disorders task force on rating scales for Parkinson's disease. Mov Disord. 2009 Apr 15; 24(5):635-46.
Score: 0.003
-
Evaluating Parkinson's disease patients at home: utility of self-videotaping for objective motor, dyskinesia, and ON-OFF assessments. Mov Disord. 2008 Jul 30; 23(10):1479-82.
Score: 0.003
-
Sialorrhea in Parkinson's disease: a review. Mov Disord. 2007 Dec; 22(16):2306-13.
Score: 0.003
-
The range of motor activation in the normal human cortex using bold FMRI. Brain Topogr. 2006; 18(4):273-80.
Score: 0.003
-
Single-blind clinical trial of psychotherapy for treatment of psychogenic movement disorders. Parkinsonism Relat Disord. 2006 Apr; 12(3):177-80.
Score: 0.002
-
Transcultural comparison of psychogenic movement disorders. Mov Disord. 2005 Oct; 20(10):1343-5.
Score: 0.002